Nymox Pharma Reports No Material Changes To Content Of Planned Applications For Its Benign Prostatic Hyperplasia Treatment; Says Unavoidable Delays Have Been Incurred But Co. 'Highly Confident' Filings Will Occur In Near-Term Horizon, Likely In Q1'21